WO2026078093A1 - Immunoglobulines anti-gangliosides ayant une activité accrue - Google Patents

Immunoglobulines anti-gangliosides ayant une activité accrue

Info

Publication number
WO2026078093A1
WO2026078093A1 PCT/EP2025/079027 EP2025079027W WO2026078093A1 WO 2026078093 A1 WO2026078093 A1 WO 2026078093A1 EP 2025079027 W EP2025079027 W EP 2025079027W WO 2026078093 A1 WO2026078093 A1 WO 2026078093A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
dinutuximab
produced
antibodies
qarziba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/079027
Other languages
English (en)
Inventor
Muriel Bardor
Christelle FÉCOURT
Manon SALVETTI
Camille NZUE
Chloé PLACINES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alga Biologics
Original Assignee
Alga Biologics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alga Biologics filed Critical Alga Biologics
Publication of WO2026078093A1 publication Critical patent/WO2026078093A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre des antigènes tumoraux de ganglioside qui peuvent être obtenus dans Phaeodactylum tricornutum, lesdits anticorps présentant une très grande affinité FcRn et une activité de cytotoxicité directe accrue ; leurs utilisations en tant que médicament et plus particulièrement, pour le traitement du cancer.
PCT/EP2025/079027 2024-10-08 2025-10-08 Immunoglobulines anti-gangliosides ayant une activité accrue Pending WO2026078093A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2410844A FR3167160A1 (fr) 2024-10-08 2024-10-08 Immunoglobulines avec affinite augmentee pour le fcrn
FRFR2410844 2024-10-08

Publications (1)

Publication Number Publication Date
WO2026078093A1 true WO2026078093A1 (fr) 2026-04-16

Family

ID=94598524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/079027 Pending WO2026078093A1 (fr) 2024-10-08 2025-10-08 Immunoglobulines anti-gangliosides ayant une activité accrue

Country Status (2)

Country Link
FR (1) FR3167160A1 (fr)
WO (1) WO2026078093A1 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188638A (en) 1986-03-27 1987-10-07 Gregory Paul Winter Chimeric antibodies
EP0531472A1 (fr) 1991-03-06 1993-03-17 MERCK PATENT GmbH Anticorps monoclonaux humanises et chimeriques
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO2008043777A1 (fr) 2006-10-10 2008-04-17 Universite De Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
EP1817340B1 (fr) 2004-11-12 2012-05-16 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
EP2660324A1 (fr) * 2012-05-02 2013-11-06 Algenics Production d'anticorps thérapeutiques sécrétés dans des micro-algues
EP2660323A1 (fr) * 2012-05-02 2013-11-06 Algenics Production d'anticorps thérapeutiques sécrétés dans des microalgues phaeodctylum tricornutum
WO2013164095A1 (fr) * 2012-05-02 2013-11-07 Algenics Production d'anticorps thérapeutiques sécrétés dans des microalgues
EP2164873B1 (fr) 2007-05-31 2015-09-30 Genmab A/S Anticorps igg4 stables
EP2552955B1 (fr) 2010-03-30 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Anticorps avec une affinite modifiee pour fcrn pour augmenter la clairance des antigenes
WO2023208883A1 (fr) 2022-04-26 2023-11-02 Universite De Rouen Normandie Production d'anticorps thérapeutiques par microalgue phaeodactylum tricornutum

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
DK1896071T3 (en) 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188638A (en) 1986-03-27 1987-10-07 Gregory Paul Winter Chimeric antibodies
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
EP0531472A1 (fr) 1991-03-06 1993-03-17 MERCK PATENT GmbH Anticorps monoclonaux humanises et chimeriques
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1817340B1 (fr) 2004-11-12 2012-05-16 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
WO2008043777A1 (fr) 2006-10-10 2008-04-17 Universite De Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
EP2164873B1 (fr) 2007-05-31 2015-09-30 Genmab A/S Anticorps igg4 stables
EP2552955B1 (fr) 2010-03-30 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Anticorps avec une affinite modifiee pour fcrn pour augmenter la clairance des antigenes
EP3181581B1 (fr) 2010-03-30 2024-09-25 Chugai Seiyaku Kabushiki Kaisha Anticorps ayant une affinité modifiée pour fcrn pour augmenter la clairance des antigènes
EP2660324A1 (fr) * 2012-05-02 2013-11-06 Algenics Production d'anticorps thérapeutiques sécrétés dans des micro-algues
EP2660323A1 (fr) * 2012-05-02 2013-11-06 Algenics Production d'anticorps thérapeutiques sécrétés dans des microalgues phaeodctylum tricornutum
WO2013164095A1 (fr) * 2012-05-02 2013-11-07 Algenics Production d'anticorps thérapeutiques sécrétés dans des microalgues
WO2023208883A1 (fr) 2022-04-26 2023-11-02 Universite De Rouen Normandie Production d'anticorps thérapeutiques par microalgue phaeodactylum tricornutum

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Ullmann's Encyclopedia of Industrial Chemistry", 1989, MARCEL DEKKER
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1994, WILLIAMS & WILKINS
BAZ ET AL., ONCOL. THER, vol. 4, no. 2, 2016, pages 287 - 30
CANCER RES, vol. 65, no. 14, 2005, pages 6425 - 6434
COCHONNEAU ET AL., CANCER LETT., vol. 333, no. 2, 2013, pages 194 - 204
DAMELANG ET AL., FRONTIERS IN IMMUNOLOGY, vol. 14, 2024
DIXON ET AL., CANCERS, vol. 13, 2021, pages 312
DORONIN ET AL., BMC CANCER, vol. 14, 2014, pages 295
DORVIGNIT ET AL., ABOVEMENTIONED, 2015
DORVIGNIT ET AL., IMMUNOBIOLOGY, vol. 220, no. 12, 2015, pages 1343 - 1350
DUMONTIER ET AL., CARBOHYDR. POLYM, vol. 259, 2021, pages 117660
DUMONTIER RODOLPHE ET AL: "Identification of N-glycan oligomannoside isomers in the diatom Phaeodactylum tricornutum", CARBOHYDRATE POLYMERS, vol. 259, 1 May 2021 (2021-05-01), GB, pages 117660, XP093350690, ISSN: 0144-8617, DOI: 10.1016/j.carbpol.2021.117660 *
GA�TAN VANIER ET AL: "Alga-Made Anti-Hepatitis B Antibody Binds to Human Fc[gamma] Receptors", BIOTECHNOLOGY JOURNAL, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 13, no. 4, 27 December 2017 (2017-12-27), pages n/a, XP072423489, ISSN: 1860-6768, DOI: 10.1002/BIOT.201700496 *
HEMPEL ET AL., MICROB. CELL FACT, vol. 16, 2017, pages 131
HEMPEL ET AL., PLOS ONE, vol. 6, 2011, pages 28424
HEMPELMAIER, MICROB. CELL FACT, vol. 11, 2012, pages 126
HOUGHTON ET AL., PROC NATL ACAD SCI U S A, vol. 82, no. 4, 1985, pages 1242 - 6
HUPAN: "Electroporation Transformation Protocol for Phaeodactylum tricornutum", METHODS MOL. BIOL, vol. 2050, 2020, pages 163 - 167
KHATOON ET AL., DESALINATION AND WATER TREATMENT, vol. 57, no. 60, 2016, pages 29295 - 29302
KRISTAL ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23169 - 75
NAKAMURA ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 50, no. 5, 2001, pages 275 - 84
PARAJULI ET AL., CANCER LETT., vol. 165, no. 2, 2001, pages 179 - 84
PEREZ HORTA ET AL., IMMUNOTHERAPY, vol. 8, 2016, pages 1097 - 1117
SAXENAWU, FRONTIERS IN IMMUNOLOGY, vol. 7, 2016
SORKIN ET AL., PAIN, vol. 149, 2010, pages 135 - 142
VAN DER HORST ET AL., CANCERS, vol. 12, 2020, pages 3041
VANIER ET AL., BIOTECHNOL. J, vol. 13, 2018, pages 1700496
VANIER ET AL., PLOS ONE, vol. 10, no. 10, 2015, pages 0139282
ZALEVSKY ET AL., NAT. BIOTECHNOL., vol. 28, no. 2, 2010, pages 157 - 159

Also Published As

Publication number Publication date
FR3167160A1 (fr) 2026-04-10

Similar Documents

Publication Publication Date Title
KR102871856B1 (ko) c-Kit에 대한 인간화 항체
US11407828B2 (en) Anti-CLauDiN 18 antibodies and methods of use thereof
ES2906823T3 (es) Anticuerpos agonistas que se unen específicamente a CD40 humano y métodos de uso
JP7620807B2 (ja) 抗ＳＩＲＰα抗体およびその適用
JP2018512175A (ja) グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
CN113906052A (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
WO2019059771A2 (fr) Anticorps anti-gd2 pour le traitement d'un neuroblastome
JP7397444B2 (ja) コンドロイチン硫酸プロテオグリカン－５に結合する抗体
IL323937A (en) Bifunctional degraders of galactose-deficient immunoglobulins
EP3994147A1 (fr) Épitope tau et molécules de liaison
JP2023544140A (ja) 新規の抗クローディン１８抗体
WO2022002988A1 (fr) Molécules de liaison à tau
WO2023028525A2 (fr) Anticorps pilra et méthodes d'utilisation de ceux-ci
WO2026078093A1 (fr) Immunoglobulines anti-gangliosides ayant une activité accrue
WO2024165028A1 (fr) Anticorps anti-cd16a et leurs utilisations
US20250326840A1 (en) BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE
US20250297026A1 (en) Therapeutic antibodies
WO2023116770A1 (fr) MOLÉCULES DE LIAISON POUR FCγRIIA ET LEUR UTILISATION
WO2021043203A1 (fr) Anticorps anti-cxcr2 et leurs utilisations
US20240336681A1 (en) Anti-cd47 antibodies and use thereof
CN116375873A (zh) 抗人Siglec-9单克隆抗体及其用途
TW202432574A (zh) 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
WO2026052782A1 (fr) Anticorps anti-globo h
WO2025229206A1 (fr) Molécules de liaison monovalentes anti-iga et procédés d'utilisation
WO2025206223A1 (fr) Anticorps anti-claudine 18,2 humaine et son utilisation